The Caledonian-Record

Subcutaneous PD-1 Inhibitors Transition from Novelty to Routine Care as Oncologists Tailor Use ...

The U.S. market for PD-1 inhibitors has entered a new phase of evolution. According to the latest RealTime Dynamix™: PD-1 Inhibition in ...

Subcutaneous PD-1 Inhibitors Transition from Novelty to Routine Care as Oncologists Tailor Use by Tumor Type, According to Spherix Global Insights

Oncologists have moved beyond evaluating subcutaneous PD-1 inhibitors as convenient alternatives to intravenous therapy, instead incorporating them into disease-specific treatment strategies as ...

Will Keytruda Remain the Driving Force Behind Merck's Q2 Performance?

Detailed price information for Roche Holding Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.
Solicitors Journal

Patents Court rejects MSD's bid for wider Mayne Pharma disclosure in Halozyme hyaluronidase dispute

The Patents Court has dismissed an application by Merck Sharp & Dohme (UK) Limited seeking further disclosure of experimental ...

Merck: 'Strong Buy' Lipfendra FDA First And Continued Oncology Expansions

Strong Buy on oncology pipeline gains and LIPFENDRA launch, with KEYTRUDA patent risks. Click for this MRK update.
Morning Overview on MSN

Regulators cleared Keytruda with chemo before and after surgery for aggressive bladder cancer

Adults diagnosed with muscle-invasive bladder cancer gained a new treatment option on July 10, 2026, when the FDA cleared the ...
Oncology Nurse Advisor

Subcutaneous Sarclisa Escena Receives FDA Nod for Multiple Myeloma

FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.

Merck (MRK) Wins FDA Nod For New Keytruda Bladder Cancer Use

Merck (NYSE:MRK) received FDA approval for expanded use of Keytruda and Keytruda QLEX combinations with Padcev in ...

FDA Expands MRK & PFE's Keytruda-Padcev Combo Use in Bladder Cancer

Merck's Keytruda in combination with Pfizer's Padcev wins FDA nod for expanded use in muscle-invasive bladder cancer, ...
Medscape

FDA Expands Pembrolizumab-Enfortumab Vedotin Regimen in MIBC

Pembrolizumab plus enfortumab vedotin is now approved for all adults with muscle-invasive bladder cancer undergoing cystectomy.

Merck, Pfizer, Astellas Bladder Cancer Treatment Approved by FDA

The Food and Drug Administration approved a combination treatment by Merck & Co., Pfizer, and Astellas Pharma for a hard-to-treat form of bladder cancer. The agency greenlit Merck's Keytruda and its ...
Monthly Prescribing Reference

FDA Expands Perioperative Keytruda + Padcev Approval for MIBC

In the phase 3 KEYNOTE-B15/EV-304 trial, perioperative pembrolizumab plus enfortumab vedotin reduced the risk of recurrence, progression, or death by 47% and improved overall survival by 35% over ...